This column provides reports that situate and synthesize current developments, issues, innovative clinical procedures, therapeutic methods and promising novel methods of delivery in the related fields of palliative care.
Get full access to this article
View all access options for this article.
References
1.
VilligerJW. Binding of buprenorphine to opiate receptors. Regulation by guanyl nucleotides and metal ions. Neuropharmacology1984; 23/3:373–375.
2.
BoasRA, VilligerJW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth1985; 57:192–196.
3.
HeelRC, BrogdenRN, SpeightTM, AveryGS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs1979; 17:81–110.
4.
RanceMJ. Animal and molecular pharmacology of mixed agonist-antagonist analgesic drugs. Br J Clin Pharmacol1979; 7: 281S–286S.
5.
WHO Cancer Pain Relief.Geneva: World Health Organization1986; 14–23.
6.
AdriaensenH, MattelaereB, VanmeenenH.A long-term open assessment of sublingual buprenorphine in patients suffering from chronic pain. Pain1981; 1:38S.
7.
RobbieDA. A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmacol1979; 7:315S–317S.
8.
VentafriddaV, DeConnoF, GuariseG, TamburiniM, SavioG.Chronic analgesic study on buprenorphine action in cancer pain. Comparison with pentazocine. Arzneim-Forsch/Drug Res1983; 33:587–590.
9.
De ConnoF, RipamontiC, SbanottoA, BarlettaL, ZeccaE, MartiniC, VentafriddaV.A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. J Pain Sympt Mánag1991; 6: 423–427.
10.
TamburiniM, SelmiS, De ConnoF, VentafriddaV.Semantic descriptors of pain. Pain1987; 25:187–193.
11.
VentafriddaV, De ConnoF, Di TrapaniP, GallicoS, RigamontiG, TamburiniM.A new method of pain quantification based on a weekly self-descriptive record of the intensity and duration of pain. In: BonicaJJ, LindholmU, IggoA (eds). Advances in Pain research and Therapy, Volume 5. New York: Raven Press1983; pp. 891–895.
12.
HambrookJM, RanceMJ. The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz (ed). Opiates and Endogenous Opioid Peptides. Amsterdam: Elsevier/North Holland Biomedical Press1976; pp. 295–301.
13.
GalTJ. Naloxone reversal of buprenorphine-induced respiratory depression. ClinPharm Ther1989; 45:66–71.
14.
JasinskiDR. Discussion. In: FoleyKM, InturrusiCE (eds). Advances in Pain Research and Therapy, Opioid Analgesics in the Management of Clinical Pain, Volume 8. New York: Raven Press1986; pp. 279–283.
15.
GoldbergRJ, MorV, WiemannM, GreerDS, HiusJ.Analgesic use in terminal cancer patients: report from the National Hospice Study. J Chron Dis1986; 39 (1):37–45.
16.
InturrusiCE. Management of the cancer pain. Pharmacology and principles of management. Cancer1989; 63: 2308–2320.
